Bipolar I Depression

The short version

●Bipolar I disorder is defined by at least one lifetime manic episode; the depressive episodes that dominate its long-term course are often more disabling and harder to treat than the mania.
●Bipolar depression is treated differently from unipolar depression: mood stabilizers (lithium, lamotrigine, quetiapine, lurasidone) are the foundation, and antidepressants alone risk triggering mania or rapid cycling.
●Lithium has the strongest anti-suicidal evidence of any psychiatric medication and is a cornerstone of bipolar I care.
●A randomized controlled add-on trial (Diazgranados 2010) found a single ketamine infusion, on top of a mood stabilizer, produced rapid antidepressant effect in treatment-resistant bipolar depression.
●Ketamine for bipolar depression is given with mood-stabilizer protection in place, because the bipolar diathesis raises the theoretical risk of mood switching.
●Ketamine is not first-line; it is considered for treatment-resistant bipolar I depression already covered by an adequate mood stabilizer.

Clinical definition

Bipolar I disorder is defined by at least one manic episode — a distinct period of abnormally elevated, expansive, or irritable mood with increased energy lasting at least one week (or any duration if hospitalization is required), accompanied by symptoms such as grandiosity, decreased need for sleep, pressured speech, racing thoughts, distractibility, and risky behavior. Although mania defines the diagnosis, most patients spend far more time in the depressive pole: episodes of depressed mood, anhedonia, sleep and appetite change, worthlessness, and suicidal ideation that are clinically indistinguishable in the moment from unipolar major depression. The critical distinction is the lifetime history of mania, because it changes treatment entirely — an antidepressant given without mood-stabilizer cover can precipitate a manic switch or accelerate cycling. Bipolar I depression carries a high suicide risk and frequently presents as "treatment-resistant depression" when the underlying bipolarity has not been recognized.

How it differs from related conditions

vs. Unipolar major depression

Identical depressive symptoms in the moment, but no lifetime mania; treatment differs fundamentally (antidepressant-first in unipolar, mood-stabilizer-first in bipolar). Missed bipolarity is a common cause of apparent antidepressant failure.

vs. Bipolar II depression

Defined by hypomania (not full mania) plus depression; the depressive burden is similarly heavy, and lamotrigine and quetiapine feature prominently.

vs. Borderline personality disorder

Affective instability can mimic bipolar cycling, but BPD mood shifts are rapid (hours), reactive to interpersonal triggers, and lack the sustained, episodic mood elevation with decreased sleep need seen in mania.

vs. Schizoaffective disorder

Includes mood episodes but adds psychotic symptoms that occur independently of mood episodes.

First-line treatments

Mood stabilizers (lithium, lamotrigine)

Lithium is foundational with unmatched anti-suicidal evidence; lamotrigine is particularly effective for the depressive pole and is weight-neutral.

Atypical antipsychotics with bipolar-depression evidence

Quetiapine, lurasidone, and cariprazine are FDA-approved for bipolar depression and used as monotherapy or adjuncts.

Combination (mood stabilizer + atypical)

Common for moderate-to-severe episodes; the foundation is always a stabilizer, not an antidepressant alone.

Cautious adjunctive antidepressants

Only with mood-stabilizer cover and careful monitoring for switching; many guidelines de-emphasize antidepressants in bipolar I.

When standard treatments fail

Treatment-resistant bipolar depression is inadequate response despite adequate trials of mood stabilizers and bipolar-depression-approved atypicals. The escalation path: confirm adherence and therapeutic lithium levels → optimize or combine stabilizers and atypicals → add or switch to lamotrigine, lurasidone, or cariprazine → consider ECT (highly effective for severe bipolar depression) → consider rapid-acting glutamatergic options including ketamine for the refractory subgroup, always with mood-stabilizer protection. Psychotherapy (CBT, IPSRT, family-focused therapy) and rigorous sleep and rhythm regulation are essential adjuncts throughout.

Where ketamine fits

Ketamine has been investigated specifically in bipolar depression, not merely extrapolated from unipolar studies. In randomized, placebo-controlled, add-on trials in patients already maintained on a mood stabilizer (Diazgranados 2010, Archives of General Psychiatry; replicated by the same group), a single ketamine infusion produced rapid antidepressant effects in treatment-resistant bipolar depression, including rapid reduction in suicidal ideation, with low rates of treatment-emergent mania when mood-stabilizer cover was in place. That last point is the crux: the bipolar diathesis raises the theoretical risk of a manic or hypomanic switch, so ketamine for bipolar I depression is given only with an adequate mood stabilizer already on board and with monitoring for activation. Ketamine is not first-line; it is a consideration for treatment-resistant bipolar I depression where stabilizers and approved atypicals have not produced sufficient relief.

Where this fits with Tovani

Bipolar I disorder requires careful handling in an at-home model. Tovani treats bipolar I depression only when the patient is established on an adequate mood stabilizer managed by a prescribing clinician, and eligibility screening specifically captures bipolar history, the current stabilizer regimen, and any history of mood switching — precisely because unrecognized bipolarity is a common reason "treatment-resistant depression" has not responded. Patients are monitored for signs of activation or switching between sessions, and a trusted support person is required. Bipolar I patients who are not on a mood stabilizer, or who are acutely manic, mixed, or unstable, are not candidates for at-home ketamine and are referred for stabilization first.

Check eligibility The science behind ketamine

Frequently asked

Is ketamine safe in bipolar disorder — won't it trigger mania?

The controlled bipolar-depression trials gave ketamine on top of a mood stabilizer and found low rates of treatment-emergent mania. The safeguard is the stabilizer: Tovani treats bipolar I depression only when an adequate mood stabilizer is already in place, and monitors for any signs of activation or switching.

Why can't I just take an antidepressant for bipolar depression?

Because an antidepressant without mood-stabilizer cover can precipitate mania or speed up cycling in bipolar I. The foundation of treatment is a mood stabilizer (lithium, lamotrigine) or a bipolar-depression-approved atypical, not an antidepressant alone.

My "depression" never responded to antidepressants — could it be bipolar?

It is worth a careful evaluation. Unrecognized bipolarity is a common reason depression appears treatment-resistant, and it changes treatment entirely. Tovani's screening asks specifically about any history of manic or hypomanic symptoms.

Does ketamine help bipolar suicidal thoughts?

In the controlled bipolar-depression trials, ketamine produced rapid reductions in suicidal ideation alongside the antidepressant effect. This is one of the most clinically meaningful findings, but it is delivered within a structured plan with mood-stabilizer protection — not as a standalone crisis treatment. If you are in crisis, call or text 988.

References

Diazgranados N et al. 2010, Archives of General Psychiatry — Randomized add-on trial of an NMDA antagonist (ketamine) in treatment-resistant bipolar depression; rapid antidepressant effect on top of a mood stabilizer, with low rates of treatment-emergent mania. (PMID 20679587)
Cipriani A et al. 2018, The Lancet — Network meta-analysis of antidepressant efficacy and acceptability — context for the limited, cautious role of antidepressants in bipolar depression. (PMID 29477251)
Murrough JW et al. 2013, American Journal of Psychiatry — Ketamine RCT establishing rapid antidepressant response in treatment-resistant depression. (PMID 23982301)

Last reviewed by Dr. Ben Soffer, DO on May 30, 2026. This page is educational and not a substitute for clinical evaluation. A physician determines whether ketamine therapy is appropriate for your specific situation.